Colorectal Cancer: Characterization of a new Cre-LoxP Model
结直肠癌:新 Cre-LoxP 模型的表征
基本信息
- 批准号:9307305
- 负责人:
- 金额:$ 6.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-15 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AwardBudgetsCancer EtiologyCancer ModelCancer PatientCarcinomaCell Culture TechniquesCell Differentiation processCell LineageCell ProliferationCessation of lifeColorectal CancerCre-LoxPDataDevelopmentEmbryoEpithelialEpithelial CellsFibroblastsFoundationsFundingGene DeletionGenesGoalsHomeostasisHumanImmunocompromised HostIn VitroIndividualInternationalIntestinesInvestigationLaboratoriesLoxP-flanked alleleMalignant NeoplasmsMitogen-Activated Protein Kinase KinasesModelingMusMutant Strains MiceNeoplasm MetastasisNon-Small-Cell Lung CarcinomaOncogenesOncogenicPathway interactionsPatient riskPhenotypePress ReleasesPreventiveProteinsPublicationsReceptor Protein-Tyrosine KinasesRegulationReportingResearch PersonnelResourcesRoleSignal PathwaySignal TransductionTamoxifenTestingTherapeuticTimeTransfectionUnited Statesbasecancer cellcarcinogenesiscareerepithelial to mesenchymal transitionevidence basehigh riskin vitro Modelin vivointestinal homeostasismigrationmortalitymouse modelnovelpostnatalsmall molecule inhibitortumortumor progressiontumorigenesisvillin
项目摘要
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality in the United States. In
our recent reports, we demonstrated tumor promoting role of Sprouty2, an endogenous suppressor of
receptor tyrosine kinase (RTK)/ Mitogen Activated Protein Kinase (MAPK) signaling pathways in
colorectal cancer (CRC). In order to establish in vivo role of Sprouty2 in cancer we recently generated
Sprouty2F/F mouse in our laboratory. The objectives of this RO3 application are to characterize the
model and study the effect of embryonic (Sprouty2F/F-Villin Cre) and postnatal (Sprouty2F/F-Villin
CreERT2) deletion of Sprouty2 on CRC progression. Our rationale for these studies is that establishing
in vivo role of Sprouty2 gene in CRC would allow us to submit a mechanistic RO1 application.
In vitro studies from our laboratory utilizing cell culture models, orthotopic and metastasis mouse
models demonstrated oncogenic potential of Sprouty2 in CRC. In preliminary studies, we also
established that TAT dependent Sprouty2 protein transduction or Sprouty2 stable transfection favors
cancer phenotype. On the contrary suppression of Sprouty2 supports epithelial features in cancer cells
and murine embryonic fibroblasts (MEFs) obtained from Sprouty2F/F-Villin CreERT2 mouse. However,
requirement of Sprouty2 in CRC progression in vivo is not established. Effect of embryonic and
postnatal Sprouty2 deletion in Sprouty2F/F-Villin Cre (embryonic deletion) and Sprouty2F/F-Villin CreERT2
mouse (tamoxifen dependent postnatal deletion), respectively, will be studied during AOM/DSS induced
colonic carcinogenesis. We will also examine effect of Sprouty2 deletion in vivo on intestinal cell
differentiation and lineage by utilizing both mice groups.
To our knowledge, this is the first study to demonstrate the effect of in vivo deletion of SPRY2 on CRC
progression and intestinal cell lineage. We have established our hypothesis based on our past and
recent publications. The proposed study is a multi-prong approach to prepare us for a RO1 application.
结直肠癌(CRC)是美国癌症相关死亡率的主要原因之一。在
我们最近的报道,我们证明了Sputy 2的肿瘤促进作用,Sputy 2是一种内源性抑制剂,
受体酪氨酸激酶(RTK)/丝裂原活化蛋白激酶(MAPK)信号通路在
结直肠癌(CRC)。为了确定Sprouty 2在癌症中的体内作用,我们最近产生了
Sprouty 2F/F小鼠。本RO 3应用程序的目标是表征
研究了胚胎期(Sprouty 2F/F-Villin Cre)和出生后(Sprouty 2F/F-Villin Cre)的作用
CreERT 2)Sprouty 2缺失对CRC进展的影响。我们进行这些研究的理由是,
Sprouty 2基因在CRC中体内作用将允许我们提交机械RO 1应用。
我们实验室利用细胞培养模型进行的体外研究,原位和转移小鼠
模型证实Sprouty 2在CRC中的致癌潜力。在初步研究中,我们还
证实达特依赖性Sputy 2蛋白转导或Sputy 2稳定转染有利于
癌症表型。相反,Sprouty 2的抑制支持癌细胞中的上皮特征
和从Sprouty 2F/F-Villin CreERT 2小鼠获得的鼠胚胎成纤维细胞(MEF)。然而,在这方面,
Sprouty 2在体内CRC进展中的需求尚未建立。胚胎和
Sputy 2F/F-Villin Cre(胚胎缺失)和Sputy 2F/F-Villin CreERT 2中的出生后Sputy 2缺失
小鼠(他莫昔芬依赖性出生后缺失)的研究将分别在AOM/DSS诱导期间进行
结肠癌发生我们还将研究Sprouty 2缺失对体内肠细胞的影响,
分化和谱系。
据我们所知,这是第一个证明体内缺失SPRY 2对CRC影响的研究
进展和肠细胞谱系。我们根据过去的经验建立了我们的假设,
最近的出版物。拟议的研究是一个多管齐下的方法,为我们准备的RO 1应用程序。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHARAD KHARE其他文献
SHARAD KHARE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHARAD KHARE', 18)}}的其他基金
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid
熊去氧胆酸的结肠癌化学预防和 COX-2 抑制
- 批准号:
8391604 - 财政年份:2011
- 资助金额:
$ 6.08万 - 项目类别:
SPROUTY: PUTATIVE ONCOGENE IN COLORECTAL CANCER
Sprouty:结直肠癌中的假定癌基因
- 批准号:
9239686 - 财政年份:2011
- 资助金额:
$ 6.08万 - 项目类别:
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid
熊去氧胆酸的结肠癌化学预防和 COX-2 抑制
- 批准号:
8141038 - 财政年份:2011
- 资助金额:
$ 6.08万 - 项目类别:
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid
熊去氧胆酸的结肠癌化学预防和 COX-2 抑制
- 批准号:
8601404 - 财政年份:2011
- 资助金额:
$ 6.08万 - 项目类别:
Colon Cancer Chemoprevention by Ursodeoxycholic Acid
熊去氧胆酸化学预防结肠癌
- 批准号:
6616118 - 财政年份:2002
- 资助金额:
$ 6.08万 - 项目类别:
Colon Cancer Chemoprevention by Ursodeoxycholic Acid
熊去氧胆酸化学预防结肠癌
- 批准号:
6849035 - 财政年份:2002
- 资助金额:
$ 6.08万 - 项目类别:
Colon Cancer Chemoprevention by Ursodeoxycholic Acid
熊去氧胆酸化学预防结肠癌
- 批准号:
6548254 - 财政年份:2002
- 资助金额:
$ 6.08万 - 项目类别:
相似海外基金
Can megafauna shift the carbon and surface radiation budgets of the Arctic?
巨型动物群能否改变北极的碳和地表辐射预算?
- 批准号:
NE/W00089X/2 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
Research Grant
Resilience of pollinators in a changing world: impact of developmental environment on metabolism and energetic budgets in social and solitary bees
不断变化的世界中授粉媒介的复原力:发育环境对群居和独居蜜蜂新陈代谢和能量预算的影响
- 批准号:
BB/X016641/1 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
Research Grant
An innovative EDI data, insights & peer benchmarking platform enabling global business leaders to build data-led EDI strategies, plans and budgets.
创新的 EDI 数据、见解
- 批准号:
10100319 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
Collaborative R&D
Nutrient budgets as a tool for minimizing nitrogen and phosphorus losses from agricultural fields
养分预算作为最大限度减少农田氮磷损失的工具
- 批准号:
574867-2022 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
University Undergraduate Student Research Awards
Sea-ice Snow Microbial Communities’ Impact on Antarctic Bromocarbon Budgets and Processes
海冰雪微生物群落对南极溴碳预算和过程的影响
- 批准号:
2031121 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
Standard Grant
Collaborative Research: ORCC: The role of bioenergetic budgets in defining elevation limits and modeling geographic ranges of species
合作研究:ORCC:生物能预算在定义海拔限制和建模物种地理范围中的作用
- 批准号:
2222475 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
Standard Grant
Collaborative Research: ORCC: The role of bioenergetic budgets in defining elevation limits and modeling geographic ranges of species
合作研究:ORCC:生物能预算在定义海拔限制和建模物种地理范围中的作用
- 批准号:
2222476 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
Continuing Grant
CNS Core: Small: Budgets, Budgets Everywhere: A Necessity for Safe Real-Time on Multicore
CNS 核心:小:预算,预算无处不在:多核安全实时的必要性
- 批准号:
2151829 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
Standard Grant
The Effect of Aggressive Mitigation of non-CO2 Emissions on Global Carbon Budgets
积极减少非二氧化碳排放对全球碳预算的影响
- 批准号:
559571-2021 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
Postgraduate Scholarships - Doctoral
Can megafauna shift the carbon and surface radiation budgets of the Arctic?
巨型动物群能否改变北极的碳和地表辐射预算?
- 批准号:
NE/W00089X/1 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
Research Grant